2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular …
S Halvorsen, J Mehilli, S Cassese, TS Hall… - European heart …, 2022 - academic.oup.com
Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …
evidence shows that it can be considered medically appropriate to a given condition and if …
2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association …
JS Lawton, JE Tamis-Holland, S Bangalore, ER Bates… - Circulation, 2022 - Am Heart Assoc
Aim: The executive summary of the American College of Cardiology/American Heart
Association/Society for Cardiovascular Angiography and Interventions coronary artery …
Association/Society for Cardiovascular Angiography and Interventions coronary artery …
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …
Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Writing Committee Members, JS Lawton… - Journal of the American …, 2022 - jacc.org
Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …
Acute coronary syndromes
BA Bergmark, N Mathenge, PA Merlini… - The Lancet, 2022 - thelancet.com
Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …
coronary syndromes, cardiovascular disease remains the leading cause of death globally …
2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary …
H Watanabe, T Morimoto, M Natsuaki… - JAMA …, 2022 - jamanetwork.com
Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …
Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO …
BK Kim, SJ Hong, YH Cho, KH Yun, YH Kim, Y Suh… - Jama, 2020 - jamanetwork.com
Importance Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was
evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy …
evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy …
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
M Valgimigli, F Gragnano, M Branca, A Franzone… - Bmj, 2021 - bmj.com
Objective To assess the risks and benefits of P2Y 12 inhibitor monotherapy compared with
dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' …
dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' …
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS …
CJ Kim, MW Park, MC Kim, EH Choo, BH Hwang… - The Lancet, 2021 - thelancet.com
Background In patients with acute myocardial infarction receiving potent antiplatelet therapy,
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …